摘要
目的：观察和探讨卡马西平联合敏使朗治疗前庭阵发症的临床疗效。方法：选取2010年9月～2012年2月经我院眩晕门诊诊断的前庭阵发症患者86例，将患者随机分为卡马西平联合敏使朗组（43例）和卡马西平组（43例），观察2组的疗效。结果：卡马西平联合敏使朗组的有效率高于卡马西平组，差异有统计学意义（P〈0，05），而且不良反应少。结论：卡马西平联合敏使朗治疗前庭阵发症的临床疗效好、安全性高，值得临床推广使用。
Objective：To evaluate the clinical efficiency of carbamazepine combined with mestilate for treatment of vestibular pamxys- mia. Methods ： Eighty - six patients suffering from vestibular paroxysmia were underwent the research, they were randomly divided into two groups, the carbamazepine combined with mestilate group（43case） and the carbmazepine group （43case）, the effficacy of the two groups were observed. Results：The efficiency rate in the carbamazepine combined with mestilate group was higher than the carbamazepine group （ P 〈 0.05 ）. The side effects of carbamazepine combined with mestilate group were generally mild. Conclusion： Carbamazepine combined with mestilate in treatment of vestibular paroxysmia had good clinical curative effect, highly safety, should be worth clinical use
出处
《中国伤残医学》
2013年第10期41-42,共2页
Chinese Journal of Trauma and Disability Medicine
关键词
卡马西平
敏使朗
前庭阵发症
疗效
Carbamazepine
Mestilate
Vestibular paroxysmia
Efficiency
